Low Vision Awareness Month 2018
With this exclusive content, find out more about what lessons can be learned from the Japanese first-in-human age-related macular degeneration trial.
For Low Vision Awareness Month 2018, we’ve been reflecting on arguably the biggest trial in regenerative medicine; Masayo Takahashi’s first-in-human age-related macular degeneration trial using iPSC-derived tissue.
With this exclusive content, find out more about what lessons can be learned and how it could affect future vision research.
The mounting excitement about regenerative medicine as a ‘dream therapy’, put the five committees reviewing Masayo Takahashi’s first-in-human trial of iPSC-derived tissue for macular degeneration under significant stress during the review process from 2012 to 2013. In this commentary, find out what can be learned from analysis of the committee minutes and what they could mean for future trials.
In this interview, Masayo Takahashi, Project Leader for Laboratory for Retinal Regeneration at the RIKEN Centre for Developmental Biology (Kobe, Japan), explains techniques being utilized in the first iPSC clinical trial in humans, halted in 2015, and how lessons learnt could affect the trial procedure when it was restarted in 2017.
In the world’s first clinical trial utilizing allogeneic iPSC-derived retinal cells to treat age-related macular degeneration, the first serious adverse reaction was reported in mid-January. What was this reaction, and could it affect future trials?